Navigation Links
Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010
Date:9/7/2010

Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on... -- HARBIN, China, Sept. 7 /PRNewswire-Asia-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
OTC, SmallCap, Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Trade Show News Click to view news release full screen  

Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010

 

HARBIN, China, Sept. 7 /PRNewswire-Asia-FirstCall/ -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that it will participate in the Rodman and Renshaw Annual Global Investment Conference on Tuesday, September 14th, 2010.

Conference: Rodman and Renshaw Annual Global Investment Conference Date: Tuesday, September 14th 2010 Time: 4:30 - 4:55 PM ET Location: Kennedy Salon (4th FL), New York Palace Hotel New York, New York

Mr. Ren Hu, Vice President of Finance of Weikang, will present the Company's operations, business strategy, financial results, and outlook as well as answer investors' questions during the presentation and at one-on-one meetings.

Investors interested in attending the event should contact their Rodman and Renshaw sales representative. For more information about the conference, please visit http://www.rodmanandrenshaw.com/ .

About Weikang Bio-Technology Group Co., Inc.

Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang. For more information, please visit http://www.weikangbio.com .

Safe Harbor Statement

This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

For further information, please contact: Company contact: Ren Hu, VP of Finance Weikang Bio-Technology Group Co., Inc. US Cell: +1-201-887-0415 Email: arenhu@gmail.com Investors Relation contacts: John Marco, Partner, Elite IR Tel: +1-310-819-2948 Email: John.marco@elite-ir.com Leslie J. Richardson, Partner, Elite IR Tel: +852-3183-0283 Email: Leslie.richardson elite-ir.com
'/>"/>

SOURCE Weikang Bio-Technology Group Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Weikang Bio-Technology Reports Second Quarter 2010 Financial Results
2. Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference
3. Lexicon to Present at Morgan Stanley Global Healthcare Conference
4. Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference
5. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
6. The Female Health Company to Present at Rodman & Renshaws Annual Global Investment Conference on Wednesday, September 15, 2010
7. Sequenom to Present at Two Financial Conferences in September
8. Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups
9. Marrone Bio Innovations to Present Invasive Mussel Control Solution
10. MO BIO Laboratories, Inc. DNA Isolation Products Used to Analyze Microbes Present in Deepwater Horizon Oil Plume
11. Access Pharmaceuticals Presents at American Chemical Society Annual Fall Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... 9, 2016 DelveInsight,s, ... report provides in depth insights on the ... the Protein-Tyrosine Phosphatase 1B (PTP1B) Inhibitors. The ... various stages of development including Discovery, Pre-clinical, ... and Preregistration. Report covers the product clinical ...
(Date:2/8/2016)... 8, 2016 Should antibiotic bone cement products ... to prevent infection after standard total hip or knee ... ECRI Institute have been fielding a lot lately. ... Bottom Line?" --> "Antibiotic Bone ... --> While there isn,t a simple ...
(Date:2/8/2016)... 2016 --> ... innovation-driven oncology company developing next generation cancer therapeutics ... announced that chairman emeritus of Tata Sons Limited, ... company as part of the first close of ... Navam Capital and Aarin Capital. http://photos.prnewswire.com/prnh/20150923/766442 ...
(Date:2/8/2016)... ... February 08, 2016 , ... Thomas J. Todorow has joined ... President for Corporate Services and the Chief Financial Officer at The Children’s Hospital ... Treasury, Managed Care Contracting, Supply Chain, and Investments. , Prior to joining CHOP ...
Breaking Biology Technology:
(Date:1/20/2016)... 20, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce the attainment ... are the result of the company,s laser focus on ... , it,s comprehensive, easy-to-use and highly affordable cloud-based ... Key MedNet growth achievements in 2015 include: ...
(Date:1/13/2016)... January 13, 2016 ... addition of the  "India Biometrics Authentication ... Forecast (2015-2020)"  report to their ... has announced the addition of the  ... - Estimation & Forecast (2015-2020)" ...
(Date:1/7/2016)... This BCC Research report studies the global ... devices, identifying newer markets and exploring the expansion of ... devices. Includes forecast from 2015 to 2020. ... explore the expansion of the present application market for ... biometric technology, determine its current market size, and estimate ...
Breaking Biology News(10 mins):